Work Description

MEDLINE (PubMed)
1.
("Neoplasms"[Mesh] OR neoplasm[tw] OR cancer[tw] OR cancers[tw] OR cancerous[tw] OR tumor[tw] OR tumors[tw] OR oncology[tw] OR neoplasms[tw] OR carcinoma[tw] OR Malignancy[tw] OR Malignancies[tw] OR Leukemia[tw] OR Leukemias[tw] OR gliomas[tw] OR glioma[tw] OR Neurofibromas[tw] OR Neurofibromatosis[tw] OR Melanoma[tw] OR Melanomas[tw]) AND ("Pediatrics"[Mesh:NoExp] OR "Infant"[Mesh] OR "Child"[Mesh] OR "Adolescent"[Mesh] OR infant[tw] OR infants[tw] OR baby[tw] OR babies[tw] OR child[tw] OR children[tw] OR kid[tw] OR teen[tw] OR teenager[tw] OR teens[tw] OR teenagers[tw] OR youth[tw] OR adolescent[tw] OR adolescents[tw] OR adolescence[tw] OR Pediatrics[tw] OR Pediatric[tw] OR paediatric[tw] OR paediatrics[tw])

2.
"MAP Kinase Kinase Kinases"[Mesh] OR "Anaplastic Lymphoma Kinase"[Mesh] OR (("Anaplastic lymphoma kinase"[tw] OR ALK[tw]) AND (inhibitor[tw] OR inhibitors[tw])) OR "Crizotinib"[Mesh] OR alectinib[tw] OR ceritinib[tw] OR "PF-02341066"[tw] OR "PF-2341066"[tw] OR "PF 2341066"[tw] OR PF2341066[tw] OR "PF 02341066" [tw] OR PF02341066[tw] OR Xalkori[tw] OR Crizotinib[tw] OR (MEK[tw] AND (inhibitors[tw] OR inhibitor[tw])) OR "Mitogen activated protein kinase"[tw] OR Trametinib[tw] OR GSK1120212[tw] OR Cobimetinib[tw] OR XL518[tw] OR Binimetinib[tw] OR "MAP Kinase Kinase Kinases"[tw] OR Brigatinib[tw] OR Lorlatinib[tw] OR Refametinib[tw] OR Selumetinib [tw] OR Pimasertib [tw] OR Mirdametinib[tw]

3.
"Chemically-Induced Disorders"[Mesh] OR "chemically induced" [Subheading] OR "Drug-Related Side Effects and Adverse Reactions"[Mesh] OR "Long Term Adverse Effects"[Mesh] OR "drug effects" [Subheading:NoExp] OR "adverse effects" [Subheading] OR "Dysgeusia"[Mesh] OR "Diarrhea"[Mesh] OR "adverse effects" [tw] OR "side effects"[tw] OR "adverse effect"[tw] OR "side effect"[tw] OR toxicities[tw] OR toxicity[tw] OR "Drug Event"[tw] OR "Drug Events"[tw] OR reaction[tw] OR reactions[tw] OR dermatological[tw] OR dermatologic[tw] OR cutaneous[tw] OR rash[tw] OR rashes[tw] OR dermal[tw] OR dermatitis[tw] OR Gastrointestinal[tw] OR "Loss of taste"[tw] OR Diarrhea[tw] OR dysgeusia[tw]

1 AND 2 AND 3
Limits: English

Embase

1.
('neoplasm'/exp OR (neoplasm OR cancer OR cancers OR cancerous OR tumor OR tumors OR oncology OR neoplasms OR carcinoma OR Malignancy OR Malignancies OR Leukemia OR Leukemias OR gliomas OR glioma OR Neurofibromas OR Neurofibromatosis OR Melanoma OR Melanomas):ti,ab,de,tn) AND ('pediatrics'/exp OR 'infant'/exp OR 'child'/exp OR 'adolescent'/exp OR (infant OR infants OR baby OR babies OR child OR children OR kid OR teen OR teenager OR teens OR teenagers OR youth OR adolescent OR adolescents OR adolescence OR Pediatrics OR Pediatric OR paediatric OR paediatrics):ti,ab,de,tn)

2
'crizotinib'/exp OR 'anaplastic lymphoma kinase'/exp OR (("Anaplastic lymphoma kinase" OR ALK) AND (inhibitor OR inhibitors)):ti,ab,de,tn OR (alectinib OR ceritinib OR PF-02341066 OR PF-2341066 OR "PF 2341066" OR PF2341066 OR "PF 02341066" OR PF02341066 OR Xalkori OR Crizotinib):ti,ab,de,tn OR 'mitogen activated protein kinase kinase kinase'/exp OR (MEK AND (inhibitors OR inhibitor)):ti,ab,de,tn OR ("Mitogen activated protein kinase" OR Trametinib OR GSK1120212 OR Cobimetinib OR XL518 OR Binimetinib OR "MAP Kinase Kinase Kinases" OR Brigatinib OR Lorlatinib OR Refametinib OR Selumetinib OR Pimasertib OR Mirdametinib):ti,ab,de,tn

3.
'chemically induced disorder'/exp OR 'adverse drug reaction'/exp OR 'dysgeusia'/exp OR 'diarrhea'/exp OR ("adverse effects" OR "side effects" OR "adverse effect" OR "side effect" OR toxicities OR toxicity OR "Drug Event" OR "Drug Events" OR reaction OR reactions OR dermatological OR dermatologic OR cutaneous OR rash OR rashes OR dermal OR dermatitis OR Gastrointestinal OR "Loss of taste" OR Diarrhea OR dysgeusia):ti,ab,de,tn

1 AND 2 AND 3
Limits: English

CINAHL Complete Plus (EBSCO)

1.
(MH "Neoplasms+" OR neoplasm OR cancer OR cancers OR cancerous OR tumor OR tumors OR oncology OR neoplasms OR carcinoma OR Malignancy OR Malignancies OR Leukemia OR Leukemias OR gliomas OR glioma OR Neurofibromas OR Neurofibromatosis OR Melanoma OR Melanomas) AND (MH "Pediatrics+" OR MH "Infant+" OR MH "Child+" OR MH "Adolescence" OR MH "Adolescent, Hospitalized" OR infant OR infants OR baby OR babies OR child OR children OR kid OR teen OR teenager OR teens OR teenagers OR youth OR adolescent OR adolescents OR adolescence OR Pediatrics OR Pediatric OR paediatric OR paediatrics)

2.
MH "Mitogen-Activated Protein Kinases" OR MH "Protein-Tyrosine Kinases" OR MH "Anaplastic Lymphoma Kinase" OR (("Anaplastic lymphoma kinase" OR ALK) AND (inhibitor OR inhibitors)) OR alectinib OR ceritinib OR "PF-02341066" OR "PF-2341066" OR "PF 2341066" OR PF2341066 OR "PF 02341066" OR PF02341066 OR Xalkori OR Crizotinib OR (MEK AND (inhibitors OR inhibitor)) OR "Mitogen activated protein kinase" OR Trametinib OR GSK1120212 OR Cobimetinib OR XL518 OR Binimetinib OR "MAP Kinase Kinase Kinases" OR "mitogen activated protein kinase kinase kinase" OR Brigatinib OR Lorlatinib OR Refametinib OR Selumetinib OR Pimasertib OR Mirdametinib OR "Tyrosine Kinase Inhibitors"

3.
MH "Drug Toxicity+" OR MW “AE” OR MH "Dysgeusia" OR MH "Diarrhea" OR "adverse effects" OR "side effects" OR "adverse effect" OR "side effect" OR toxicities OR toxicity OR "Drug Event" OR "Drug Events" OR reaction OR reactions OR dermatological OR dermatologic OR cutaneous OR rash OR rashes OR dermal OR dermatitis OR Gastrointestinal OR "Loss of taste" OR Diarrhea OR dysgeusia

1 AND 2 AND 3
Limits: Source Type: Academic Journals, English

Cochrane Library (Wiley)

Search Name: COGEBP updated on 11/18/20
Date Run: 19/11/2020 00:02:51
Comment:

ID Search Hits
#1 MeSH descriptor: [Neoplasms] explode all trees 79239
#2 (neoplasm OR cancer OR cancers OR cancerous OR tumor OR tumors OR oncology OR neoplasms OR carcinoma OR Malignancy OR Malignancies OR Leukemia OR Leukemias OR gliomas OR glioma OR Neurofibromas OR Neurofibromatosis OR Melanoma OR Melanomas):ti,ab,kw 222522
#3 #1 OR #2 228471
#4 MeSH descriptor: [Pediatrics] explode all trees 674
#5 MeSH descriptor: [Infant] explode all trees 31920
#6 MeSH descriptor: [Child] explode all trees 55653
#7 MeSH descriptor: [Adolescent] explode all trees 103482
#8 (infant OR infants OR baby OR babies OR child OR children OR kid OR teen OR teenager OR teens OR teenagers OR youth OR adolescent OR adolescents OR adolescence OR Pediatrics OR Pediatric OR paediatric OR paediatrics):ti,ab,kw 273847
#9 #4 OR #5 OR #6 OR #7 OR #8 273856
#10 MeSH descriptor: [Anaplastic Lymphoma Kinase] explode all trees 42
#11 MeSH descriptor: [Crizotinib] explode all trees 70
#12 MeSH descriptor: [MAP Kinase Kinase Kinases] explode all trees 171
#13 ((("Anaplastic lymphoma kinase" OR ALK) AND (inhibitor OR inhibitors)) OR alectinib OR ceritinib OR "PF-02341066" OR "PF-2341066" OR "PF 2341066" OR PF2341066 OR "PF 02341066" OR PF02341066 OR Xalkori OR Crizotinib OR (MEK AND (inhibitors OR inhibitor)) OR "Mitogen activated protein kinase" OR Trametinib OR GSK1120212 OR Cobimetinib OR XL518 OR Binimetinib OR "MAP Kinase Kinase Kinases" OR "mitogen activated protein kinase kinase kinase" OR Brigatinib OR Lorlatinib OR Refametinib OR Selumetinib OR Pimasertib OR Mirdametinib):ti,ab,kw 1521
#14 #10 OR #11 OR #12 OR #13 1645
#15 MeSH descriptor: [Chemically-Induced Disorders] explode all trees 19392
#16 MeSH descriptor: [Drug-Related Side Effects and Adverse Reactions] explode all trees 3595
#17 MeSH descriptor: [Long Term Adverse Effects] explode all trees 30
#18 MeSH descriptor: [Dysgeusia] explode all trees 40
#19 MeSH descriptor: [Diarrhea] explode all trees 3506
#20 ("adverse effects" OR "side effects" OR "adverse effect" OR "side effect" OR toxicities OR toxicity OR "Drug Event" OR "Drug Events" OR reaction OR reactions OR dermatological OR dermatologic OR cutaneous OR rash OR rashes OR dermal OR dermatitis OR Gastrointestinal OR "Loss of taste" OR Diarrhea OR dysgeusia):ti,ab,kw 374367
#21 #15 OR #16 OR #17 OR #18 OR #19 OR #20 386298
#22 #3 AND #9 AND #14 AND #21 44

Scopus (Elsesvier)

TITLE-ABS-KEY(((neoplasm OR cancer OR cancers OR cancerous OR tumor OR tumors OR oncology OR neoplasms OR carcinoma OR Malignancy OR Malignancies OR Leukemia OR Leukemias OR gliomas OR glioma OR Neurofibromas OR Neurofibromatosis OR Melanoma OR Melanomas) AND (infant OR infants OR baby OR babies OR child OR children OR kid OR teen OR teenager OR teens OR teenagers OR youth OR adolescent OR adolescents OR adolescence OR Pediatrics OR Pediatric OR paediatric OR paediatrics)) AND ((("Anaplastic lymphoma kinase" OR ALK) AND (inhibitor OR inhibitors)) OR alectinib OR ceritinib OR "PF-02341066" OR "PF-2341066" OR "PF 2341066" OR PF2341066 OR "PF 02341066" OR PF02341066 OR Xalkori OR Crizotinib OR "MAP Kinase Kinase Kinases" OR (MEK AND (inhibitors OR inhibitor)) OR "Mitogen activated protein kinase" OR Trametinib OR GSK1120212 OR Cobimetinib OR XL518 OR Binimetinib OR "mitogen activated protein kinase kinase kinase" OR Brigatinib OR Lorlatinib OR Refametinib OR Selumetinib OR Pimasertib OR Mirdametinib OR "Tyrosine Kinase Inhibitors") AND ("adverse effects" OR "side effects" OR "adverse effect" OR "side effect" OR toxicities OR toxicity OR "Drug Event" OR "Drug Events" OR reaction OR reactions OR dermatological OR dermatologic OR cutaneous OR rash OR rashes OR dermal OR dermatitis OR Gastrointestinal OR "Loss of taste" OR Diarrhea OR dysgeusia))

Limits: English. Document type: Articles and Reviews

Professional Organizations

Oncology Nursing Society https://www.ons.org/
Search: Search: 0 results
Journals: https://www.ons.org/journals
* Clinical Journal of Oncology Nursing (Indexed in PubMed)
* Oncology Nursing Forum (Indexed in PubMed)
* Magazine: ONS Voice
* 5 results:
* http://voice.ons.org/news-and-views/stay-current-on-evolving-therapies-in-melanoma
* http://voice.ons.org/news-and-views/how-targeted-therapies-are-changing-treatment-for-non-small-cell-lung-cancer
* http://voice.ons.org/news-and-views/manage-adverse-events-from-immunotherapy-and-targeted-therapy-for-melanoma
* http://voice.ons.org/news-and-views/manage-common-ocular-toxicities-from-tyrosine-kinase-inhibitors
* http://voice.ons.org/news-and-views/fda-approves-combination-of-mekinist-and-tafinlar-for-advanced-melanoma

Society of International Pediatric Oncology https://siop-online.org/
* Search: 0 results
* Journal: https://siop-online.org/journal/
https://onlinelibrary.wiley.com/journal/15455017
* Pediatric Blood and Cancer (PBC) (Indexed in PubMed)

American Society of Clinical Oncology https://www.asco.org/
* Search: "Anaplastic lymphoma kinase inhibitors" OR "ALK inhibitors" OR "mitogen activated protein kinase inhibitors" OR "MEK inhibitors" site:asco.org
* Filetype:pdf
* Journals: https://ascopubs.org/
* Journal of Clinical Oncology (Indexed in PubMed)
* https://ascopubs.org/journal/jco
* "J Clin Oncol"[jour]
* JCO Oncology Practice (Indexed in PubMed)
* JCO Global Oncology (Indexed in PubMed)
* JCO Clinical Cancer Informatics (Indexed in PubMed)
* JCO Precision Oncology (Indexed in PubMed)

Association of Pediatric Hematology/ Oncology Nurses https://aphon.org/
* Search: "Anaplastic lymphoma kinase inhibitors" OR "ALK inhibitors" OR "mitogen activated protein kinase inhibitors" OR "MEK inhibitors" site:aphon.org/
* Journal: Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses (Indexed in PubMed)

American Society of Pediatric Hematology/Oncology http://aspho.org/
* Search : "Anaplastic lymphoma kinase inhibitors" OR "ALK inhibitors" OR "mitogen activated protein kinase inhibitors" OR "MEK inhibitors" site:aspho.org/
* Journal: same as Society of International Pediatric Oncology: Pediatric Blood and Cancer (Indexed in PubMed)

Children’s Oncology Group https://www.childrensoncologygroup.org/
* Search: "Anaplastic lymphoma kinase inhibitors" OR "ALK inhibitors" OR "mitogen activated protein kinase inhibitors" OR "MEK inhibitors" site:childrensoncologygroup.org/